Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial

Blood (2024) 144 (Supplement 1): 3158.

https://doi.org/10.1182/blood-2024-205465

Published: 2024

Journal Articles

Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma

Noémie Leblay, Sungwoo Ahn, Holly Lee, Matteo Claudio Da Vià, Mansour Poorebrahim, Sacha Benaoudia, David Jung, Elham Hasheminasabgorji, Niccolò Bolli, Nizar J. Bahlis, Paola Neri

Blood (2024) 144 (Supplement 1): 4642.

https://doi.org/10.1182/blood-2024-208842

Published: 2024

Journal Articles

Intrinsic and Microenvironmental Determinants of AML Response to HMA-Venetoclax Therapy at the Single-Cell Transcriptomic Level

Alfredo Marchetti, Francesca Lazzaroni, Matteo Claudio Da Vià, Alessio Marella, Antonio Matera, Akihiro Maeda, Nicolo Rampi, Claudia Leoni, Federico Mazzon, Elena Tagliaferri, Mariarita Sciumè, Marta Lionetti, Bruno Fattizzo, Francesco Passamonti, Nicola Stefano Fracchiolla, Niccolò Bolli

Blood (2024) 144 (Supplement 1): 2928.

https://doi.org/10.1182/blood-2024-208253

Published: 2024

Journal Articles

Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients

Daniele Cattaneo, Barbara Mora, Cristina Bucelli, Margherita Maffioli, Elena Maria Elli, Giulia Benevolo, Valentina Bellani, Emilia Scalzulli, Filippo Branzanti, Paola Bianchi, Marta Lionetti, Bruno Martino, Umberto Gianelli, Niccolò Bolli, Francesca Palandri, Massimo Breccia, Dario Consonni, Alessandra Iurlo

Blood (2024) 144 (Supplement 1): 4550.

https://doi.org/10.1182/blood-2024-211145

Published: 2024

Journal Articles

Genomic and Immune Determinants of Resistance to Anti-CD38 MoAb Based Therapy in Relapsed Multiple Myeloma

Bachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, Giuseppe Bertuglia, Elona Saraci, Stefania Oliva, Benjamin Diamond, Niccolò Bolli, Paolo Corradini, David Coffey, Ola Landgren, Benedetto Bruno, Mario Boccadoro, Massimo Massaia, Francesco Maura, Alessandra Larocca

Blood (2023) 142 (Supplement 1): 1966.

https://doi.org/10.1182/blood-2023-182301

Published: 2023

Journal Articles

Novel Combinatorial Therapeutic Options in NEAT1-Depleted Multiple Myeloma Cells By the Integration of in Vitro and in silico Drug Screening Approaches

Noemi Puccio, Elisa Taiana, Gloria Manzotti, Elisabetta Mereu, Domenica Ronchetti, Cecilia Bandini, Ilaria Craparotta, Laura Di Rito, Marco Bolis, Veronica Manicardi, Valentina Fragliasso, Nicola Amodio, Niccolò Bolli, Stefano Luminari, Alessia Ciarrocchi, Roberto Piva, Antonino Neri

Blood (2023) 142 (Supplement 1): 6612.

https://doi.org/10.1182/blood-2023-190131

Published: 2023

Journal Articles

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Blood (2023) 142 (Supplement 1): 6393.

https://doi.org/10.1182/blood-2023-181521

Published: 2023

Journal Articles

Prevalence, Characteristics, and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential in AL Amyloidosis

Paolo Lopedote, Alfredo Marchetti, Benjamin Evans, Tianzeng Chen, Maria Moscvin, Niccolò Bolli, Giada Bianchi

Blood (2023) 142 (Supplement 1): 2029.

https://doi.org/10.1182/blood-2023-190905

Published: 2023

Journal Articles

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Blood (2023) 141 (19): 2359–2371.

https://doi.org/10.1182/blood.2022018244

Published: 2023

Includes: Supplemental data

Journal Articles

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 1561–1563.

https://doi.org/10.1182/blood-2022-160215

Published: 2022

Journal Articles

Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures

Blood (2022) 140 (Supplement 1): 2088–2090.

https://doi.org/10.1182/blood-2022-158992

Published: 2022

Journal Articles

Real-Life Outcome of Patients with Newly Diagnosed Symptomatic Multiple Myeloma Treated with VTD Induction Followed By Single or Double ASCT: A Retrospective Analysis from a Single Institution

Fabio Serpenti, Anushka Shankar, Nicolo' Rampi, Cristina Mocellin, Cecilia Fidanza, Maria Cecilia Goldaniga, Giorgia Saporiti, Matteo Claudio Da Via, Giulia Galassi, Loredana Pettine, Filippo Bagnoli, Niccolo Bolli, Luca Baldini, Alessandra Pompa, Francesco Onida

Blood (2022) 140 (Supplement 1): 12576–12577.

https://doi.org/10.1182/blood-2022-169454

Published: 2022

Journal Articles

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 1121–1124.

https://doi.org/10.1182/blood-2022-163634

Published: 2022

Journal Articles

Clinical relevance of clonal hematopoiesis in persons aged ≥80 years

Marianna Rossi, Manja Meggendorfer, Matteo Zampini, Mauro Tettamanti, Emma Riva, Erica Travaglino, Matteo Bersanelli, Sara Mandelli, Alessia Antonella Galbussera, Ettore Mosca, Elena Saba, Chiara Chiereghin, Nicla Manes, Chiara Milanesi, Marta Ubezio, Lucio Morabito, Clelia Peano, Giulia Soldà, Rosanna Asselta, Stefano Duga, Carlo Selmi, Maria De Santis, Karolina Malik, Giulia Maggioni, Marilena Bicchieri, Alessia Campagna, Cristina A. Tentori, Antonio Russo, Efrem Civilini, Paola Allavena, Rocco Piazza, Giovanni Corrao, Claudia Sala, Alberto Termanini, Laura Giordano, Paolo Detoma, Aurelio Malabaila, Luca Sala, Stefano Rosso, Roberto Zanetti, Claudia Saitta, Elena Riva, Gianluigi Condorelli, Francesco Passamonti, Armando Santoro, Francesc Sole, Uwe Platzbecker, Pierre Fenaux, Niccolò Bolli, Gastone Castellani, Wolfgang Kern, George S. Vassiliou, Torsten Haferlach, Ugo Lucca, Matteo G. Della Porta

Blood (2021) 138 (21): 2093–2105.

https://doi.org/10.1182/blood.2021011320

Published: 2021

Includes: Supplemental data

Journal Articles

MGUS and Chip: Two Faces, but Not of the Same Medal

Matteo Claudio Da Via, Marta Lionetti, Antonio Matera, Erica Travaglino, Ugo Lucca, Emma Riva, Mauro Tettamanti, Luca Baldini, Antonino Neri, Matteo G. Della Porta, Niccolo Bolli

Blood (2021) 138 (Supplement 1): 3800.

https://doi.org/10.1182/blood-2021-147890

Published: 2021

Journal Articles

Dissection of Bone Marrow Microenvironment By Single Cell RNA Sequencing in Warm AIHA Patients: A Proof-of-Concept Analysis

Bruno Fattizzo, Matteo Claudio Da Via', Juri Alessandro Giannotta, Paola Bianchi, Luca Baldini, Niccolo Bolli, Wilma Barcellini

Blood (2021) 138 (Supplement 1): 931.

https://doi.org/10.1182/blood-2021-149546

Published: 2021

Journal Articles

Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms

Blood (2021) 138 (Supplement 1): 3271.

https://doi.org/10.1182/blood-2021-145927

Published: 2021

Journal Articles

Cereblon enhancer methylation and IMiD resistance in multiple myeloma

Blood (2021) 138 (18): 1721–1726.

https://doi.org/10.1182/blood.2020010452

Published: 2021

Includes: Supplemental data

Journal Articles

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Blood (2021) 138 (18): 1705–1720.

https://doi.org/10.1182/blood.2020010572

Published: 2021

Includes: Supplemental data

Journal Articles

Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma

Matteo Claudio Da Via', MD, Bachisio Ziccheddu, Matteo Dugo, Marta Lionetti, PhD, Katia Todoerti, PhD, Mattia D'Agostino, MD, Antonino Neri, MD, Luca Baldini, MD PhD, Paolo Corradini, Francesco Maura, MD, Niccolo Bolli, MD PhD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-136211

Published: 2020

NARROW

Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma

Intrinsic and Microenvironmental Determinants of AML Response to HMA-Venetoclax Therapy at the Single-Cell Transcriptomic Level

Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients

Genomic and Immune Determinants of Resistance to Anti-CD38 MoAb Based Therapy in Relapsed Multiple Myeloma

Novel Combinatorial Therapeutic Options in NEAT1-Depleted Multiple Myeloma Cells By the Integration of in Vitro and in silico Drug Screening Approaches

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Prevalence, Characteristics, and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential in AL Amyloidosis

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures

Real-Life Outcome of Patients with Newly Diagnosed Symptomatic Multiple Myeloma Treated with VTD Induction Followed By Single or Double ASCT: A Retrospective Analysis from a Single Institution

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Clinical relevance of clonal hematopoiesis in persons aged ≥80 years

MGUS and Chip: Two Faces, but Not of the Same Medal

Dissection of Bone Marrow Microenvironment By Single Cell RNA Sequencing in Warm AIHA Patients: A Proof-of-Concept Analysis

Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms

Cereblon enhancer methylation and IMiD resistance in multiple myeloma

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only